The TRIM47 antibody is a research tool designed to detect and study TRIM47 (Tripartite Motif-containing Protein 47), a member of the TRIM protein family. TRIM proteins are characterized by conserved RING, B-box, and coiled-coil domains, and many function as E3 ubiquitin ligases involved in diverse cellular processes, including immune regulation, apoptosis, and cancer progression. TRIM47. located on chromosome 17q25.3. has gained attention for its potential roles in tumorigenesis. Studies suggest it is overexpressed in several cancers, such as colorectal carcinoma, glioma, and non-small cell lung cancer, where it may promote cell proliferation, migration, and invasion by modulating pathways like Wnt/β-catenin or PI3K/AKT. Its upregulation has also been linked to poor patient prognosis.
TRIM47 antibodies enable researchers to investigate the protein’s expression patterns, subcellular localization (often cytoplasmic or nuclear), and interactions via techniques like Western blotting, immunohistochemistry, and immunofluorescence. These studies help elucidate its biological functions and pathological relevance. While current evidence highlights TRIM47 as a potential oncogenic driver and biomarker, its precise mechanisms remain incompletely understood. Further research using TRIM47-specific antibodies could clarify its role in disease and therapeutic targeting. However, validation of antibody specificity and standardized detection protocols are critical to ensure reliable experimental outcomes.